A detailed history of Schonfeld Strategic Advisors LLC transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Schonfeld Strategic Advisors LLC holds 51,109 shares of VKTX stock, worth $2.73 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
51,109
Previous 28,642 78.44%
Holding current value
$2.73 Million
Previous $1.52 Million 113.11%
% of portfolio
0.02%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$49.84 - $70.47 $1.12 Million - $1.58 Million
22,467 Added 78.44%
51,109 $3.24 Million
Q2 2024

Aug 14, 2024

SELL
$47.39 - $80.2 $237,281 - $401,561
-5,007 Reduced 14.88%
28,642 $1.52 Million
Q1 2024

May 15, 2024

BUY
$17.4 - $94.5 $585,492 - $3.18 Million
33,649 New
33,649 $2.76 Million
Q3 2023

Nov 14, 2023

BUY
$10.92 - $16.0 $86,781 - $127,152
7,947 Added 17.29%
53,900 $596,000
Q2 2023

Aug 14, 2023

SELL
$14.84 - $24.79 $4.22 Million - $7.05 Million
-284,402 Reduced 86.09%
45,953 $744,000
Q1 2023

May 15, 2023

BUY
$8.08 - $17.33 $1.58 Million - $3.38 Million
195,211 Added 144.45%
330,355 $5.5 Million
Q4 2022

Feb 14, 2023

BUY
$2.72 - $9.4 $154,833 - $535,085
56,924 Added 72.77%
135,144 $1.27 Million
Q3 2022

Nov 14, 2022

SELL
$2.55 - $3.89 $24,225 - $36,955
-9,500 Reduced 10.83%
78,220 $213,000
Q2 2022

Aug 15, 2022

BUY
$2.11 - $3.15 $185,089 - $276,318
87,720 New
87,720 $254,000
Q3 2019

Nov 14, 2019

SELL
$6.55 - $8.6 $3.11 Million - $4.09 Million
-475,400 Closed
0 $0
Q2 2019

Aug 14, 2019

SELL
$7.67 - $10.63 $1.37 Million - $1.9 Million
-178,900 Reduced 27.34%
475,400 $3.95 Million
Q1 2019

May 15, 2019

BUY
$7.58 - $9.94 $4.96 Million - $6.5 Million
654,300 New
654,300 $6.5 Million

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $4.1B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Schonfeld Strategic Advisors LLC Portfolio

Follow Schonfeld Strategic Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.